Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome.

Project description

A novel drug to restore cognitive ability in Down syndrome patients

Down syndrome is a genetic disorder caused by the presence of an extra chromosome 21. People with Down syndrome have mild to moderate cognitive and learning deficits as well as certain physical features. Emerging evidence indicates that cognitive decline is due to the over-expression of the DYRK1A kinase in the brain. In neurons, the DYRK1A protein is involved in the formation and maturation of dendrite extensions which transmit nerve impulses. Funded by the European Innovation Council, the DOWN-AUTONOMY project will develop an inhibitor against DYRK1A protein as a novel therapeutic to reduce symptoms in Down syndrome patients.

Objective

All people with Down Syndrome (DS) suffer from a certain level of impaired learning and memory (cognitive disorders) from childhood onwards, greatly impacting their autonomy and societal integration. This is becoming an increasingly urgent issue as people with DS are more often outliving their care takers, yet an adequate treatment has not yet been developed.

Studies have revealed that the cognitive decline in people with DS is associated with overexpression of the DYRK1A protein kinase in the brain. Perha Pharmaceuticals has developed a novel therapeutic compound, Leucettinib-21 (LCTB-21), which acts as a DYRK1A inhibitor that can reduce cognitive decline in children with DS. Ultimately, this will increase the autonomy of people with DS resulting in better societal integration.

Perha Pharmaceuticals aims to outlicense LCTB-21 to a large pharmaceutical partner (e.g. Otsuka Pharmaceuticals, Intra-Cellular Therapies) following a successful phase 2a clinical trial.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

PERHA PHARMACEUTICALS SAS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 500 000,00
Address
LIEUDIT PRESQUILE DE PERHARIDY BATIMENT 1
29680 ROSCOFF
France

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Bretagne Bretagne Finistère
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 11 359 709,00
My booklet 0 0